BACKGROUND: Prostate-specific membrane antigen (PSMA) is an established target for the imaging and treatment of prostate cancer. This study focused on the preclinical evaluation of three novel PSMA inhibitors-P15, P16, and P19-which were structurally modified compared to the clinically used PSMA-617. Two main strategies were pursued: a chemical approach following the so-called reversed synthetic strategy, and the replacement of the naphthyl-based linker moiety with an analogous diphenyl-based moiety. The aim was to assess the impact of these modifications on physicochemical properties, in vitro behaviour, and in vivo pharmacokinetics following radiolabelling with ⁶⁸Ga. RESULTS: Radiolabelling of all three novel compounds with ⁶⁸Ga resulted in high radiochemical purity above 98% under physiological pH conditions and above 97% during stability testing in human plasma. All compounds exhibited hydrophilic characteristics based on partition coefficient measurements. Notable differences were observed in plasma protein binding, with P15 and P16 showing significantly lower binding compared to PSMA-617 and P19. In vitro assays using LNCaP prostate cancer cells demonstrated similar cellular uptake and internalization across all tested compounds. In vivo evaluation using Positron Emission Tomography/Computed Tomography (PET/CT) imaging in LNCaP tumour-bearing mice confirmed the tumour-targeting ability of all three inhibitors. These findings were further supported by biodistribution studies, which highlighted efficient and specific accumulation in tumour tissue. Among the tested compounds, P19 demonstrated the most promising overall profile in terms of stability, binding characteristics, and tumour uptake. CONCLUSIONS: The stereochemical modifications in the linker region significantly influenced the in vitro and in vivo behaviour of the PSMA inhibitors. Despite similar cellular uptake, differences in plasma protein binding and pharmacokinetics were evident. Among the three novel compounds, P19 emerged as a particularly promising candidate for further investigation, also indicating that the diphenyl moiety might serve as a favourable linker building block in analogy to the naphthyl moiety. Our observations suggest potential not only for diagnostic imaging with ⁶⁸Ga, but also for therapeutic applications using 177Lu, which offers a longer half-life suitable for delayed imaging and treatment intervals in prostate cancer management.

Czech Advanced Technology and Research Institute Palacky University Olomouc Hnevotinska 1333 5 Olomouc 77900 Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University Olomouc Hnevotinska 1333 5 Olomouc 77900 Czech Republic

Institute of Molecular and Translational Medicine Olomouc University Hospital Hnevotinska 1333 5 Olomouc 77900 Czech Republic

Research Group Translational Radiotheranostics German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany

Service Unit for Radiopharmaceuticals and Preclinical Studies German Cancer Research Center Im Neuenheimer Feld 280 69120 Heidelberg Germany

See more in PubMed

Al Saffar H, Chen DC, Delgado C, Ingvar J, Hofman MS, Lawrentschuk N et al. The current landscape of prostate-specific membrane antigen (PSMA) imaging biomarkers for aggressive prostate cancer. Cancers (Basel). 2024;16. PubMed PMC

Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504–17. PubMed PMC

Benešová M, Bauder-Wüst U, Schäfer M, Klika KD, Mier W, Haberkorn U, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2016;59:1761–75. PubMed

Benešová M, Guzik P, Deberle LM, Busslinger SD, Landolt T, Schibli R, et al. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy: systematic approach of varying the linker entities. Mol Pharm. 2022;19:2297–306. PubMed

Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20. PubMed

Benešová M, Umbricht CA, Schibli R, Müller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934–46. PubMed

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. PubMed PMC

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74:229–63. PubMed

Coffey DS. Similarities of prostate and breast cancer: evolution, diet, and estrogens. Urology. 2001;57:31–8. PubMed

Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem. 2001;44:298–301. PubMed

Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46:405–18. PubMed

Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–49. PubMed

Liu T, Toriyabe Y, Kazak M, Berkman CE. Pseudoirreversible Inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry. 2008;47:12658–60. PubMed

Lundmark F, Olanders G, Rinne SS, Abouzayed A, Orlova A, Rosenström U. Design, Synthesis, and evaluation of Linker-Optimised PSMA-Targeting radioligands. Pharmaceutics. 2022;14:1098. PubMed PMC

Lütje S, Slavik R, Fendler W, Herrmann K, Eiber M. PSMA ligands in prostate cancer – probe optimization and theranostic applications. Methods. 2017;130:42–50. PubMed

Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006;25:1375–84. PubMed PMC

Müller C, Struthers H, Winiger C, Zhernosekov K, Schibli R. DOTA conjugate with an albumin-binding entity enables the first folic acid–targeted 177Lu-radionuclide tumor therapy in mice. J Nucl Med. 2013;54:124–31. PubMed

Nakajima R, Nováková Z, Tueckmantel W, Motlová L, Bařinka C, Kozikowski AP. 2-Aminoadipic acid–C(O)–glutamate based prostate-specific membrane antigen ligands for potential use as theranostics. ACS Med Chem Lett. 2018;9:1099–104. PubMed PMC

Ojha B, Das G. The interaction of 5-(alkoxy)naphthalen-1-amine with bovine serum albumin and its effect on the conformation of protein. J Phys Chem B. 2010;114:3979–86. PubMed

Petrik M, Haas H, Schrettl M, Helbok A, Blatzer M, Decristoforo C. In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging. Nucl Med Biol. 2012;39:361–9. PubMed PMC

Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43:260–90. PubMed

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90. PubMed

Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62. PubMed

Ruigrok EAM, van Vliet N, Dalm SU, de Blois E, van Gent DC, Haeck J, et al. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging. 2021;48:1339–50. PubMed PMC

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103. PubMed PMC

Umbricht CA, Benešová M, Schibli R, Müller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297–306. PubMed

van der Gaag S, Bartelink IH, Vis AN, Burchell GL, Oprea-Lager DE, Hendrikse H. Pharmacological optimization of PSMA-based radioligand therapy. Biomedicines. 2022;10. PubMed PMC

Zhu J, Pan F, Cai H, Pan L, Li Y, Li L et al. Positron emission tomography imaging of lung cancer: an overview of alternative positron emission tomography tracers beyond F18 Fluorodeoxyglucose. Front Med (Lausanne). 2022;9. PubMed PMC